Literature DB >> 11438469

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

O Straume1, L A Akslen.   

Abstract

Microvessel density (MVD) was estimated in a series of 202 vertical growth phase (VPG) melanomas and 68 corresponding metastases, using a marker for angiogenic endothelial cells (CD105) and Factor-VIII. The expression pattern of vascular endothelial growth factor (VEGF), FLT-1, KDR and thrombospondin-1 (TSP-1) was studied by immunohistochemistry, in situ hybridization and reverse-transcriptase polymerase chain reaction. CD105 stained significantly less vessels, but gave only limited additional prognostic information compared with Factor-VIII, and MVD was an independent prognostic factor for both markers. Ninety-eight percent of all cases showed expression of VEGF, and higher expression was found significantly more frequent in thinner and less vascularized tumors. Possible autocrine loops were suggested by co-expression of VEGF and its two receptors in tumor cells, and by a significant correlation between KDR and tumor cell proliferation (Ki-67) in the subgroup of thicker tumors. Staining of VEGF receptors in endothelium was not correlated with MVD. Strong expression of TSP-1 in tumor stroma was found in 43% of the primary tumors, and was significantly correlated with increased thickness, proliferation and MVD, as well as decreased survival. These data suggest that MVD is associated with prognosis in cutaneous melanomas, and that the VEGF system and particularly TSP-1 seem to be involved in the regulation of angiogenesis and progression of these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438469      PMCID: PMC1850434          DOI: 10.1016/S0002-9440(10)61688-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  96 in total

1.  Angiogenesis during tumor progression in human malignant melanoma.

Authors:  D Ribatti; A Vacca; W Palma; M Lospalluti; F Dammacco
Journal:  EXS       Date:  1992

2.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

Authors:  S M Albelda; S A Mette; D E Elder; R Stewart; L Damjanovich; M Herlyn; C A Buck
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

3.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

4.  Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.

Authors:  S Y Wong; A T Purdie; P Han
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

5.  Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma.

Authors:  R L Barnhill; K Fandrey; M A Levy; M C Mihm; B Hyman
Journal:  Lab Invest       Date:  1992-09       Impact factor: 5.662

6.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

7.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

8.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

9.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.

Authors:  B I Terman; M Dougher-Vermazen; M E Carrion; D Dimitrov; D C Armellino; D Gospodarowicz; P Böhlen
Journal:  Biochem Biophys Res Commun       Date:  1992-09-30       Impact factor: 3.575

10.  The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness.

Authors:  P Carnochan; J C Briggs; G Westbury; A J Davies
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  43 in total

1.  S100A13 is a new angiogenic marker in human melanoma.

Authors:  Daniela Massi; Matteo Landriscina; Annamaria Piscazzi; Elena Cosci; Alek Kirov; Milena Paglierani; Claudia Di Serio; Vasileios Mourmouras; Stefano Fumagalli; Maurizio Biagioli; Igor Prudovsky; Clelia Miracco; Marco Santucci; Niccolò Marchionni; Francesca Tarantini
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

2.  Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Authors:  Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

3.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

4.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Authors:  Rita G Ladstein; Ingeborg M Bachmann; Oddbjørn Straume; Lars A Akslen
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

5.  EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Authors:  Faten Bougatef; Suzanne Menashi; Farah Khayati; Benyoussef Naïmi; Raphaël Porcher; Marie-Pierre Podgorniak; Guy Millot; Anne Janin; Fabien Calvo; Céleste Lebbé; Samia Mourah
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

6.  Molecular profiling of angiogenesis markers.

Authors:  Shu-Ching Shih; Gregory S Robinson; Carole A Perruzzi; Alfonso Calvo; Kartiki Desai; Jeffery E Green; Iqbal U Ali; Lois E H Smith; Donald R Senger
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 7.  Role of thrombospondin 1 in liver diseases.

Authors:  Yanzhang Li; Courtney P Turpin; Shuxia Wang
Journal:  Hepatol Res       Date:  2016-08-30       Impact factor: 4.288

8.  Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.

Authors:  Albin Jeanne; Camille Boulagnon-Rombi; Jérôme Devy; Louis Théret; Caroline Fichel; Nicole Bouland; Marie-Danièle Diebold; Laurent Martiny; Christophe Schneider; Stéphane Dedieu
Journal:  Clin Exp Metastasis       Date:  2016-06-27       Impact factor: 5.150

9.  Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.

Authors:  Kelly J Higgins; Shengxi Liu; Maen Abdelrahim; Kathryn Vanderlaag; Xinyi Liu; Weston Porter; Richard Metz; Stephen Safe
Journal:  Mol Endocrinol       Date:  2007-11-15

10.  Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Authors:  Ingeborg M Bachmann; Rita G Ladstein; Oddbjørn Straume; George N Naumov; Lars A Akslen
Journal:  BMC Cancer       Date:  2008-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.